生物活性 | |||
---|---|---|---|
描述 | SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs)[2]. DAC micelles were chemically linked onto the PAA-BP-modified stents by using N-succinimidyl-3-(2-pyridyldithiol)-propionate (SPDP) as a crosslinker[3]. The Vi (capsular polysaccharide) was bound to the porins by a heterobifunctional cross-linking reagent, N-succinimidyl-3-(2-pyridyl dithio)-propionate (SPDP)[4]. Based on the results obtained from morphological characterization, in vitro release, and therapeutic efficacy in cells, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)-modified ABNs (ABN-SPDP) was chosen. Since ABN-SPDP are formed with disulfide linkage, the drug release is facilitated under a highly reducing environment present in the tumor sites[5]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01166048 | Chronic Low Back Pain | Phase 4 | Completed | - | Austria ... 展开 >> Department of Special Anesthesia and Pain Therapy, Medical University of Vienna, AKH Vienna Vienna, Austria, 1090 收起 << |
NCT02968433 | Parkinson Disease(PD) | Phase 1 | Active, not recruiting | December 2018 | United States, California ... 展开 >> Stanford Movement Disorders Clinic Stanford, California, United States, 94304 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.20mL 0.64mL 0.32mL |
16.01mL 3.20mL 1.60mL |
32.01mL 6.40mL 3.20mL |
参考文献 |
---|